A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 5,366,862
Introduction
United States Patent 5,366,862 (hereafter “the ’862 patent”) represents a significant milestone in the development and legal protection of specific drug delivery technologies. Originally granted to Abbott Laboratories in 1994, this patent focuses on innovations related to controlled-release formulations, notably involving a particular polymer matrix facilitating sustained pharmaceutical release. Analyzing its claims and navigating the patent landscape surrounding it provides insights into its scope, influence, and potential challenges in current and future patenting strategies.
1. Overview of the ’862 Patent
The ’862 patent’s core invention pertains to a controlled-release pharmaceutical composition, which employs a polymeric matrix that modulates drug release over extended periods. Its inventive step lies in the specific use of a combination of polymers with distinct dissolution characteristics, enabling predictable, sustained delivery of active agents. Target applications ranged across various therapeutic domains, including cardiovascular, central nervous system, and analgesic drugs.
Granted on December 26, 1994, the patent’s priority date traces to provisional applications filed in the early 1990s, capturing an era of burgeoning interest in controlled-release systems. As of the current date, it has a term extending through at least December 2031, subject to patent term adjustments and extensions.
2. Claims Analysis
The claims constitute the legal backbone of the patent, delineating its scope and enforceability. The ’862 patent includes independent claims centered on the composition and the method of controlled drug delivery, supported by numerous dependent claims that specify particular polymers, drug agents, and formulation parameters.
2.1. Independent Claims
The primary independent claim broadly covers:
-
A controlled-release composition comprising a drug and a polymer matrix, wherein the polymer comprises a specific blend of polymers with defined dissolution profiles, configured to provide a sustained release over a predetermined period.
-
A method of preparing such a composition, involving blending the polymer components with the drug, followed by specific manufacturing steps.
This formulation limits scope to compositions that employ particular polymer combinations, essentially capturing a niche within the controlled-release sphere.
2.2. Dependent Claims
Dependent claims narrow the scope, specifying:
-
The type of polymers used (e.g., ethyl cellulose, hydroxypropyl cellulose).
-
The inclusion of excipients or additives, such as plasticizers and stabilizers.
-
Specific drug molecules (e.g., propranolol, lithium carbonate).
-
Manufacturing processes, including compression and extrusion parameters.
2.3. Critical Evaluation
The claims are well-drafted to constitute a robust patent portfolio for controlled-release formulations, especially with explicit polymer compositions. However, their breadth is somewhat limited: the claims do not encompass other release mechanisms (e.g., osmotic, multilayer coatings) or novel polymers developed after the patent's filing date.
From an infringement perspective, exclusivity is primarily confined to formulations employing the claimed polymer combinations and manufacturing steps before the patent’s expiry. Non-infringing alternative formulations could leverage different matrix compositions or release mechanisms.
3. Patent Landscape and Related Patents
The ’862 patent does not exist in isolation. It sits within a dense landscape of patents on controlled-release technologies, many filed during the 1980s and 1990s, emphasizing polymer design, formulation techniques, and drug delivery methods.
3.1. Neighboring Patents and Patent Families
Key related patents include:
-
U.S. Patent 4,880,488: Focuses on ethyl cellulose-based controlled-release matrices, predating the ’862 patent, and often cited in its prosecution.
-
U.S. Patent 5,043,167: Covers specific polymer blends for extended-release formulations, sharing technological lineage.
-
Worldwide patent filings: Equivalent patents exist in Europe (EP) and Japan (JP), many of which cite or are cited by the ’862 patent, creating an extensive global landscape.
3.2. Patent Citations and Influence
As a highly-cited patent, the ’862 patent influenced subsequent innovations in controlled-release systems. Its teachings underpin many later patents and research initiatives, especially those involving specific polymer blends for sustained drug delivery.
3.3. Competitive and Legal Challenges
Over the years, the ’862 patent has faced challenges:
-
Patent Litigation: While no prominent litigation directly targeting the ’862 patent is well-documented, competitors have developed alternative formulations to circumvent its claims.
-
Post-Grant Challenges: There are no notable post-grant proceedings (e.g., inter partes reviews), likely owing to the patent’s age and expiry of some claims.
-
Design-Around Strategies: Industry players have devised alternative controlled-release systems—such as osmotic pumps or multilayer coatings—that do not infringe its claims.
4. Critical Appraisal of the Significance and Limitations
The ’862 patent represents an instrumental milestone but also exemplifies typical constraints:
-
Scope Limitation: Its reliance on specific polymer blends limits applicability to inventions employing alternative polymers or mechanisms.
-
Obsolescence and Innovation: Advances in nanotechnology, biodegradable polymers, and smart delivery systems have rendered some aspects of its scope less relevant for cutting-edge formulations.
-
Legal Strength: The patent’s age, combined with known prior art, may have led to narrowing through licensing or legal assumptions. However, the claims remain sufficiently specific to offer enforceability in relevant jurisdictions.
-
Impact on Industry: The patent’s teachings underpinned many commercial products in the 1990s and early 2000s, but modern formulations tend to incorporate novel polymers outside its scope.
5. The Patent Landscape’s Strategic Implications
For innovators and patent practitioners:
-
Freedom-to-Operate (FTO): Given the patent’s historical breadth, products utilizing the patented polymer combinations would need clear clearance or licensing agreements.
-
Patentability of New Formulations: Innovations diverging from the polymer compositions or delivery mechanisms taught in the ’862 patent are potentially patentable.
-
Licensing Opportunities: Absent from active litigation, licensing arrangements remain an option, especially for companies seeking tried-and-true controlled-release platforms.
-
Anticipating Patent Expiry: With typical patent term laws—20 years from filing—the ’862 patent’s protection likely expires around 2014 or 2015, opening space for generic and innovative formulations.
6. Conclusion
The ’862 patent exemplifies a foundational controlled-release formulation patent from the 1990s, characterized by specific polymer blend claims. Its scope provided significant market exclusivity at its peak but now faces limitations due to evolving technologies and the expiration of key claims. Its influence pervades the patent landscape, supporting subsequent innovations yet also highlighting the importance of developing next-generation delivery systems that circumvent its protection.
Key Takeaways:
-
The ’862 patent’s strength stems from its specific polymer composition claims, which provided robust exclusivity during its enforceable period.
-
Modern drug delivery innovations have expanded beyond its scope, leveraging new polymers, nanotechnologies, and alternative mechanisms.
-
Navigating the patent landscape requires understanding both the narrow scope of the ’862 patent and the broader network of related patents and prior art.
-
With its expiration, a window now exists for developing novel controlled-release systems without infringing upon its claims.
-
For ongoing product development, comprehensive freedom-to-operate analyses remain essential, particularly in light of the patents’ historical influence and the evolving patent landscape.
7. FAQs
Q1: What is the primary innovation disclosed in U.S. Patent 5,366,862?
A1: It discloses a controlled-release pharmaceutical composition employing a specific polymer matrix blend that extends drug release over time, improving therapeutic efficacy and patient compliance.
Q2: Can the claims of the ’862 patent be easily circumvented?
A2: Yes. Formulations employing different polymers, alternative release mechanisms, or novel manufacturing methods outside its scope can circumvent its claims.
Q3: Is the ’862 patent still enforceable?
A3: Its primary claims have likely expired, given typical patent term laws, diminishing enforceability but still relevant for understanding patent strategies and prior art.
Q4: How did the patent landscape evolve around the ’862 patent?
A4: It influenced subsequent patents in controlled-release drug delivery, particularly those refining polymer blends, but newer technologies have introduced alternative strategies, reducing reliance on the patent.
Q5: What are the strategic considerations for companies developing controlled-release formulations today?
A5: Companies should assess existing patents like the ’862 patent for FTO, innovate beyond its scope, and consider licensing if their formulations are within its claims before expiration.
References
- U.S. Patent 5,366,862, “Controlled Release Pharmaceutical Formulations,” Abbott Laboratories, 1994.
- Additional patent references and literature cited inline during analysis.
